Quantcast

Latest Long acting beta-adrenoceptor agonist Stories

2014-09-08 08:29:55

-- LANTERN study met primary endpoint demonstrating non-inferiority of Ultibro® Breezhaler® 110/50 mcg vs Advair* Diskus* (SFC) 50/500 mcg followed by statistically significant superiority in post dose trough FEV1 after 26 weeks of treatment in patients with moderate-to-severe COPD1 -- In addition, LANTERN study met an endpoint demonstrating that Ultibro®Breezhaler ® reduced...

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-01 08:26:18

For U.S. Media Only RIDGEFIELD, Conn., Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi(®) Respimat(®) (olodaterol) Inhalation Spray 5 mcg as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STRIVERDI RESPIMAT is not indicated to treat acute...

2014-06-26 12:26:45

LONDON, June 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlookhttp://www.reportbuyer.com/pharma_healthcare/therapeutic/chronic_obstructive_pulmonary_disorder_copd_kol_insight_consensus_outlook.html The prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, its impact on the wider health economy is significant and there remains considerable...

2014-06-19 08:28:42

BURLINGTON, ON, June 19, 2014 /CNW/ - Results from a Phase III 52 week study, show tiotropium (delivered via Respimat(®)*)5µg, a once-daily long-acting anticholinergic bronchodilator, is efficacious and well-tolerated as an add-on treatment in Japanese adults with moderate to severe symptomatic asthma, despite treatment with inhaled corticosteroids (ICS) with or without long-acting beta-2 agonist (LABA). "Even with available treatments, the extent to which patients' asthma is controlled...

2014-05-15 04:22:31

OXFORD, England, May 15, 2014 /PRNewswire/ -- First full presentation of data from randomised clinical study of glycopyrronium bromide made using Prosonix' novel particle-engineering technology Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, announces that it will present results from its Phase 2 clinical study with PSX1002 in patients with moderate to severe chronic obstructive...

2014-04-28 08:32:52

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro(TM) Ellipta(®) (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the US that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of chronic obstructive pulmonary disease (COPD), is now available to retail pharmacies...

2014-01-27 16:25:06

WINSTON-SALEM, N.C., Jan. 27, 2014 /PRNewswire-USNewswire/ -- More than 25 million people in the United States have asthma, a chronic lung disease that inflames and narrows the airways causing recurring periods of wheezing, chest tightness, shortness of breath and coughing. (Logo: http://photos.prnewswire.com/prnh/20111114/DC06171LOGO) Although several types of drugs are available to treat asthma, long-acting beta agonists (LABAs) are among the most commonly used and work well for...

2014-01-27 14:57:08

More than 25 million people in the United States have asthma, a chronic lung disease that inflames and narrows the airways causing recurring periods of wheezing, chest tightness, shortness of breath and coughing. Although several types of drugs are available to treat asthma, long-acting beta agonists (LABAs) are among the most commonly used and work well for most people. However, for a small subgroup of people with asthma, LABAs can cause severe, life-threatening side effects and carry a...

2014-01-13 16:25:12

-- Ultibro(TM) Breezhaler®1(QVA149), a long-term once-daily dual bronchodilator, received Health Canada approval on December 23rd 2013 for the treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema -- Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'